Company profile
EyePoint Pharmaceuticals, Inc.
NASDAQ: EYPT · Healthcare · Biotechnology
#497 of 1,418 Healthcare companies by revenue26th-percentile growth
EA Score
58CFH 44DQ 81GM 45SS 78
v0.1 · 65/100 weight · provisional
↑ disclosure history, balance-sheet leverage · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$7.6M
Rev growth YoY (TTM)
-86.4%
Net income (FY)
-$232.0M
Employees
214
as of 2026-08-10
Market cap
$1.2B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$31.4M$31.4M2025
Net income-$232.0M-$232.0M2025
Operating income-$243.4M-$243.4M2025
Total assets$364.0M$364.0M2025
Liabilities$57.9M$57.9M2025
Equity$306.1M$306.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
License And Collaboration Agreement83%
Product7%
Y U T I Q Product7%
Royalty3%
By geography
UNITED STATES97%
CHINA3%
The read
What is EyePoint Pharmaceuticals, Inc.’s revenue?
EyePoint Pharmaceuticals, Inc. booked $31.4M in FY2025 revenue, contracting 28% year over year — slower than 74% of Healthcare companies we track, at a -739.4% net margin.
Peers · Healthcare
Nova Leap Health Corp.75B+Sonendo, Inc.——Cryo-Cell International, Inc.63CVerastem, Inc.49DFoghorn Therapeutics Inc.47DScripsAmerica, Inc.——Neighbors
Middlesex →Key facts
CEOJay S. Duker
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeNASDAQ: EYPT
Employees214
IPO date2005-01-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.